Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation
Nicoletta Cieri1, Sara Mastaglio, Giacomo Oliveira
1University Vita-Salute San Raffaele, Milan, Italy; Experimental Hematology Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy, PIBIC, San Raffaele Scientific Institute, Milan, Italy.
Hematopoietic stem cell transplantation (allo-HSCT) uses donor T cells for cancer immunotherapy. Strategies are being developed to enhance anti-tumor effects while minimizing graft-versus-host disease (GVHD).
Area of Science:
- Immunology
- Cell Therapy
- Gene Therapy
Background:
- Hematopoietic stem cell transplantation (allo-HSCT) is a potent cancer immunotherapy.
- Donor T cells in allo-HSCT offer anti-tumor activity but can cause graft-versus-host disease (GVHD).
Purpose of the Study:
- To review cell and gene therapy approaches for cancer treatment.
- To discuss strategies for enhancing anti-tumor immunity and controlling GVHD.
Main Methods:
- Review of preclinical models and clinical trials.
- Discussion of gene transfer technologies and cancer immunology.
Main Results:
- Multiple cell and gene therapy approaches are under investigation.
- These approaches aim to balance anti-tumor efficacy with GVHD mitigation.
Conclusions:
- Cell and gene therapies show promise in improving allo-HSCT outcomes.
- Further research is needed to optimize these strategies for cancer treatment.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
01:40Cell-mediated Immune Responses
01:27Tumor Immunotherapy
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
00:59Gene Therapy